A217480 Share Price Performance
₩0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
How Much Of SD Biotechnologies Co., Ltd. (KOSDAQ:217480) Do Insiders Own?
Feb 21
SD Biotechnologies Co., Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
A217480 Community Narratives
There are no narratives available yet.
Recent A217480 News & Updates
SD Biotechnologies Co., Ltd. Key Details
Last Reported Earnings
Mar 31, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -1.25k
- Gross Margin
- 17.11%
- Net Profit Margin
- -60.60%
- Debt/Equity Ratio
- 308.7%
SD Biotechnologies Co., Ltd. Competitors
Snowflake Analysis
About A217480
- Founded
- 2008
- Employees
- 247
- CEO
- WebsiteView website
SD Biotechnologies Co., Ltd. engages in the research, development, manufacture, and sale of cosmetics and skin care products in South Korea and internationally. It provides ampule masks, shining toning lines, hydra lifting masks, skin saver concentrates, oil balancing toners, foam and shave cleansers, guy brow products, defenders, sanitary napkins, feminine wash products, lip rouge and lip tint products, liquid eye tints, and glow products under the SNP, SNP prep, MSOLIC, hddn=lab, DAYWITH, and celebeau brands. The company offers its products through H&B stores, duty free shops, MART & CVS shops, and select shops, as well as online malls and other websites. SD Biotechnologies Co., Ltd. was founded in 2008 and is headquartered in Seoul, South Korea.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
South Korean Market Performance
- 7 Days: 3.3%
- 3 Months: 13.3%
- 1 Year: 32.8%
- Year to Date: 44.6%
The market has climbed 3.3% in the last 7 days, lead by the Information Technology sector with a gain of 7.1%. As for the past 12 months, the market is up 33%. Looking forward, earnings are forecast to grow by 24% annually. Market details ›